TY - JOUR
T1 - Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands
AU - Kuiper, J. G.
AU - Sanchez, R. J.
AU - Houben, E.
AU - Heintjes, E. M.
AU - Penning-van Beest, F. J. A.
AU - Khan, I.
AU - van Riemsdijk, M.
AU - Herings, R. M. C.
N1 - Kuiper, Josephina G Sanchez, Robert J Houben, Eline Heintjes, Edith M Penning-van Beest, Fernie J A Khan, Irfan van Riemsdijk, Melanie Herings, Ron M C eng Clin Ther. 2017 Apr;39(4):819-827.e1. doi: 10.1016/j.clinthera.2017.03.001. Epub 2017 Mar 27.
PY - 2017
Y1 - 2017
N2 - PURPOSE: This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands. METHODS: From the PHARMO Database Network, patients aged >/=18 years with an LDL-C measurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemic stroke, peripheral arterial disease, and diabetes mellitus. LMT use and LDL-C goal attainment at the index date was assessed. FINDINGS: Of 61 839 patients who met the inclusion criteria, 1132 (2%) had FH, 2431 (4%) had recent ACS, 6292 (10%) had coronary heart disease, 2868 (5%) had ischemic stroke, 3017 (5%) had peripheral arterial disease, and 46 099 (75%) had diabetes mellitus. Overall, 67% of patients were receiving LMT. Use of LMT ranged from 77% for recent ACS to 53% for FH, and standard-potency statins were the most prescribed. The percentage attaining an LDL-C goal of
AB - PURPOSE: This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands. METHODS: From the PHARMO Database Network, patients aged >/=18 years with an LDL-C measurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemic stroke, peripheral arterial disease, and diabetes mellitus. LMT use and LDL-C goal attainment at the index date was assessed. FINDINGS: Of 61 839 patients who met the inclusion criteria, 1132 (2%) had FH, 2431 (4%) had recent ACS, 6292 (10%) had coronary heart disease, 2868 (5%) had ischemic stroke, 3017 (5%) had peripheral arterial disease, and 46 099 (75%) had diabetes mellitus. Overall, 67% of patients were receiving LMT. Use of LMT ranged from 77% for recent ACS to 53% for FH, and standard-potency statins were the most prescribed. The percentage attaining an LDL-C goal of
KW - Adult Aged Aged, 80 and over Cholesterol, LDL/blood Coronary Disease/blood/drug therapy Diabetes Mellitus/blood/drug therapy Female Goals Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use Hyperlipoproteinemia Type II/blood/drug therapy
U2 - 10.1016/j.clinthera.2017.03.001
DO - 10.1016/j.clinthera.2017.03.001
M3 - Article
SN - 1879-114X
VL - 39
SP - 819-827 e1
JO - Clin Ther
JF - Clin Ther
IS - 4
ER -